NSAID use is associated with lower dementia and Alzheimer disease prevalence and slower cognitive decline: A retrospective longitudinal analysis of the NACC cohort

INTRODUCTION: Dementia, particularly Alzheimer disease (AD), is a major global health challenge, with prevalence projected to reach 150 million cases by 2050. AD is characterized by progressive cognitive decline linked to neuroinflammation and neurodegeneration. Non-steroidal anti-inflammatory drugs (NSAIDs) have been explored as potential neuroprotective agents, particularly diclofenac, which has been proposed to modulate microglial inflammasome signaling. However, prior studies investigating NSAIDs in AD have yielded inconsistent findings. We therefore reexamined the relationship between selected NSAIDs and dementia outcomes in a large longitudinal cohort from the National Alzheimer Coordi